US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

17 October 2014
fda-big

The US Food and Drug Administration's advisory panel has voted to keep a black box warning on US pharma major Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline).

The committee said that the warning of reports of suicide and depression should remain on the box. Some 11 members voted in favor, six members said the label should be changed and one voted to remove it. Pfizer had previously asked the US FDA to remove the warning, saying that there is no risk of increased psychiatric problems with the drug.

Benefits of Novartis’ secukinumab outweigh the risks

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical